间充质干细胞在肿瘤治疗应用的研究进展

摘要
图/表
参考文献(41)
相关文章 (10)

全文: PDF (480 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要间充质干细胞（MSCs）作为一种多能干细胞，具有广泛的生物学功能。在颅内肿瘤的治疗中，血脑屏障（BBB）的存在阻碍了药物向脑内肿瘤的扩散，药物难于达到有效的治疗。而MSCs 可绕过BBB，因此在颅内肿瘤的治疗中，其可以作为药物载体应用于肿瘤治疗。同时，经过基因修饰的MSCs，可以迁移到肿瘤局部，起到治疗肿瘤的作用，显著降低对正常细胞的毒副作用。基于已有的研究表明，MSCs 在肿瘤治疗的应用中具有广阔的前景。本文综述了关于MSCs 与肿瘤细胞的相互作用、MSCs 对肿瘤微环境的影响、MSCs 作为药物载体在肿瘤治疗上的应用以及基因修饰的MSCs 在肿瘤治疗上的应用、MSCs 分泌的细胞外囊泡（EVs）在肿瘤治疗上的应用等方面的研究进展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄仲凯
	许业炽
	徐寿雨
	朱汝森

关键词 ：间充质干细胞, 肿瘤治疗, 肿瘤微环境, 外泌体

Abstract：As a kind of pluripotent stem cells,mesenchymal stem cells (MSCs) have a wide range of biological functions.In the treatment of intracerebral tumors,the existence of blood brain barrier (BBB) hinders the diffusion of drugs to intracranial tumors,and drugs are difficult to achieve effective treatment.MSCs can bypass the BBB,so they can be used as drug carriers in the treatment of intracranial tumors.The genetically modified MSCs can migrate to the local tumor and play a therapeutic role,significantly reducing the toxic side effects on normal cells.Based on the existing studies,MSCs have a broad prospect in the application of tumor treatment.This paper reviews the interaction between MSCs and tumor cells,the effect of MSCs on the tumor microenvironment,the application of MSCs as drug carrier in tumor treatment,the genetically modified MSCs in tumor treatment,and the extracellular vesicles(EVs)secreted by MSCs in tumor treatment and other aspects of research progress.

Key words： Mesenchymal stem cell Tumor treatment Tumor microenvironment Exosomes

基金资助:广东省自然科学基金资助项目（2015A0303135 25）

通讯作者: 朱汝森，博士，主任医师，主要从事神经外科临床与科研工作

作者简介: 黄仲凯，广东医科大学2019 级外科学（神经外科）在读硕士研究生，研究方向：脑胶质瘤基因治疗

引用本文:

黄仲凯；许业炽；徐寿雨；朱汝森. 间充质干细胞在肿瘤治疗应用的研究进展[J]. 中国当代医药, 2022, 29(14): 27-31.
HUANG Zhongkai；XU Yechi；XU Shouyu；ZHU Rusen. Research progress on mesenchymal stem cells in tumor treatment. 中国当代医药, 2022, 29(14): 27-31.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I14/27

[26]	Wong S，Kong W，Fang C，et al.The TRAIL to cancer therapy：Hindrances and potential solutions[J].Crit Rev Oncol Hematol，2019，143：81-94.
[31]	Schey KL，Luther JM，Rose KL.Proteomics characterization of exosome cargo[J].Methods，2015，87：75-82.
[1]	Ostrom Q，Gittleman H，Liao P，et al.CBTRUS Statistical Report：Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014[J].Neuro Oncol，2017，19（suppl 5）：v1-v88.
[2]	Melzer C，Jacobs R，Dittmar T，et al.Reversible Growth-Arrest of a Spontaneously-Derived Human MSC-Like Cell Line[J].Int J Mol Sci，2020，21（13）：4752.
[3]	Mishra P，Mishra P，Humeniuk R，et al.Carcinoma-associated fibroblast -like differentiation of human mesenchymal stem cells[J].Cancer Res，2008，68（11）：4331-4339.
[4]	Spaeth E，Dembinski J，Sasser A，et al.Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression[J].PloS one，2009，4（4）：e4992.
[5]	Fridman W，Pagès F，Sautès-Fridman C，et al.The immune contexture in human tumours：impact on clinical outcome[J].Nat Rev Cancer，2012，12（4）：298-306.
[6]	Suzuki K，Sun R，Origuchi M，et al.Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization[J].Mol Med，2011，17（7-8）：579-587.
[7]	Djouad F，Bony C，Apparailly F，et al.Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells[J].Transplantation，2006，82（8）：1060-1066.
[23]	Srinivasan V，Gumin J，Camstra K，et al.Microcatheter delivery of neurotherapeutics：compatibility with mesenchymal stem cells[J].J Neurosurg，2019，1-9.
[24]	Marofi F，Vahedi G，Biglari A，et al.Mesenchymal Stromal/Stem Cells：A New Era in the Cell-Based Targeted Gene Therapy of Cancer[J].Front Immunol，2017，8：1770.
[25]	Zhang J，Kale V，Chen M.Gene-directed enzyme prodrug therapy[J].AAPS J，2015，17（1）：102-110.
[8]	Sasser AK，Sullivan NJ，Studebaker AW，et al.Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer[J].FASEB J，2007，21（13）：3763-3770.
[9]	Rowan BG，Gimble JM，Sheng M，et al.Human adipose tissuederived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenografts[J].PLoS One，2014，9（2）：e89595.
[10]	Christodoulou I，Goulielmaki M，Devetzi M，et al.Mesenchymal stem cells in preclinical cancer cytotherapy：a systematic review[J].Stem Cell Res Ther，2018，9（1）：336.
[11]	Wiedswang G，Borgen E，Karesen R，et al.Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer[J].J Clin Oncol，2003，21（18）：3469-3478.
[12]	Rhodes L，Muir S，Elliott S，et al.Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence[J].Breast Cancer Res Treat，2010，121（2）：293-300.
[13]	Ren G，Zhao X，Wang Y，et al.CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα[J].Cell Stem Cell，2012，11（6）：812-824.
[14]	Nishimura K，Semba S，Aoyagi K，et al.Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells[J].Pathobiology，2012，79（6）：290-306.
[15]	Martin F，Dwyer R，Kelly J，et al.Potential role of mesenchymal stem cells（MSCs）in the breast tumour microenvironment：stimulation of epithelial to mesenchymal transition （EMT）[J].Breast Cancer Res Treat，2010，124（2）：317-326.
[16]	Karnoub A，Dash A，Vo A，et al.Mesenchymal stem cells within tumour stroma promote breast cancer metastasis[J].Nature，2007，449（7162）：557-563.
[17]	Ikeda T，Nishita M，Hoshi K，et al.Mesenchymal stem cellderived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1[J].Cancer Sci，2020，111（4）：1254-1265.
[18]	Tabe Y，Konopleva M，Munsell MF，et al.PML-RARalpha is associated with leptin-receptor induction：the role of mesenchymal stem cell-derived adipocytes in APL cell survival[J].Blood，2004，103（5）：1815-1822.
[19]	Norozi F，Ahmadzadeh A，Shahrabi S，et al.Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells[J].Tumour Biol，2016，37（9）：11679-11689.
[20]	Mager L，Burkhard R，Pett N，et al.Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J].Science，2020，369（6510）：1481-1489.
[21]	Matson V，Fessler J，Bao R，et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J].Science，2018，359（6371）：104-108.
[22]	Riquelme E，Zhang Y，Zhang L，et al.Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes[J].Cell，2019，178（4）：795-806.e12.
[27]	Golinelli G，Grisendi G，Prapa M，et al.Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors[J].Cancer Gene Ther，2020，27：558-570.
[28]	Yuan Z，Kolluri K，Sage E，et al.Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand is superior to soluble type for cancer therapy[J].Cytotherapy，2015，17（7）：885-896.
[29]	Yang Z，Tang X，Guo X，et al.Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene（PTEN）：an imaging demonstration[J].Onco Targets Ther，2014，7：441-446.
[30]	Guo X，Hu Q，Yuan Y，et al.PTEN -mRNA engineered mesenchymal stem cell -mediated cytotoxic effects on U251 glioma cells[J].Oncol Lett，2016，11（4）：2733-2740.
[32]	Bernardi S，Zanaglio C，Farina M，eet al.dsDNA from extracellular vesicles（EVs）in adult AML[J].Ann Hematol，2021，100（5）：1355-1356.
[33]	Castellani C，Burrello J，Fedrigo M，et al.Circulating extracellular vesicles as non-invasive biomarker of rejection in heart transplant[J].J Heart Lung Transplant，2020，39（10）：1136-1148.
[35]	Ha D，Yang N，Nadithe V.Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes：current perspectives and future challenges[J].Acta Pharm Sin B，2016，6（4）：287-296.
[36]	Shigemoto-Kuroda T，Oh J，Kim D，et al.MSC-derived Extracellular Vesicles Attenuate Immune Responses in Two Autoimmune Murine Models：Type 1 Diabetes and Uveoretinitis[J].Stem cell reports，2017，8（5）：1214-1225.
[37]	Mendt M，Kamerkar S，Sugimoto H，et al.Generation and testing of clinical-grade exosomes for pancreatic cancer[J].JCI Insight，2018，3（8）：e99263.
[38]	Mentkowski KI，Lang JK.Exosomes Engineered to Express a Cardiomyocyte Binding Peptide Demonstrate Improved Cardiac Retention in Vivo[J].Sci Rep，2019，9（1）：10041.
[39]	Dai S，Wei D，Wu Z，et al.Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer[J].Mol Ther，2008，16（4）：782-790.
[40]	Wolfers J，Lozier A，Raposo G，et al.Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming[J].Nat Med，2001，7（3）：297-303.
[41]	Zitvogel L，Regnault A，Lozier A，et al.Eradication of established murine tumors using a novel cell-free vaccine：dendritic cell-derived exosomes[J].Nat Med，1998，4（5）：594-600.
[34]	Rikkert LG，Beekman P，Caro J，et al.Cancer-ID：Toward Identification of Cancer by Tumor-Derived Extracellular Vesicles in Blood[J].Front Oncol，2020，10：608.